HCP (NYSE:HCP), in recognition of its sustainability achievements, has
been named to CDP’s S&P 500 Climate Disclosure Leadership Index (CDLI),
as well as the Dow Jones Sustainability Index for the North American
Met primary efficacy endpoint by successfully restoring testosterone levels to the normal range in 88% of the subjects
Lower limit of the 95% confidence interval was 82%
85% of the subjects reached final dose with no more than one dose titration
Majority of subjects ended on 225 mg BID
Proportion of subjects with maximum serum concentrations generally met FDA pre-specified targets
LPCN 1021 treatment was well tolerated with no drug related serious adverse events
SALT LAKE CITY, Sept.
Hess Corporation (NYSE:HES) announced today that its wholly owned
subsidiary, Hess Midstream Partners LP, has filed a registration
statement on Form S-1 with the U.S. Securities and Exchange Commission
(SEC) related to its proposed initial public offering of common units
representing limited partner interests.
Microchip Technology Inc. (NASDAQ: MCHP), a leading provider of
microcontroller, mixed-signal, analog and Flash-IP solutions, and
AZFirst, an Arizona 501(c)3 organization supporting the FIRST ®
(For Inspiration and Recognition of Science and Technology) robotics
competitions, today announced that Grand Canyon University (GCU) will
host the first annual FIRST Arizona West Regional Competition,
from April 1-4, 2015, at its Phoenix campus.
Fibrocell Science, Inc., (NASDAQ:FCSC), an autologous cell therapy
company primarily focused on developing first-in-class treatments for
rare and serious skin and connective tissue diseases, and Intrexon
Corporation (NYSE:XON), a leader in synthetic biology, today
announced plans to file an investigational new drug (IND) application
with the U.S. Food and Drug Administration (FDA) in the first half of
2015 for their drug candidate, GM-HDF-COL7 (genetically-modified human
dermal fibroblast, collagen VII). The companies are developing this new
cell-based therapeutic for the treatment of recessive dystrophic
epidermolysis bullosa (RDEB), the most severe form of the rare
connective tissue disorder epidermolysis bullosa.
The EnLink Midstream companies, EnLink Midstream Partners, LP
(NYSE:ENLK) (the “Partnership”) and EnLink Midstream, LLC (NYSE:ENLC)
(the “General Partner”) (together “EnLink”), today announced that the
Partnership has completed the construction of Phase II of the
Cajun-Sibon natural gas liquids (NGL) expansion project in South
Tenax Therapeutics, Inc. (NASDAQ: TENX), formerly Oxygen
Biotherapeutics, Inc., a specialty pharmaceutical company focused on
developing and commercializing a portfolio of products for the critical
care market, today announced financial results for the first quarter
fiscal year 2015 ended July 31, 2014.
VeriFone Systems, Inc. (NYSE: PAY) and Vantiv,
Inc. (NYSE: VNTV)—a leading provider of payment processing services
and related technology solutions for merchants and financial
institutions of all sizes—won The Banker Technology Project of
the Year 2014 award in the Risk Management category for their
industry-leading, multi-layered approach to reducing cardholder data
security risk using end-to-end encryption.
Ares Capital Corporation (NASDAQ:ARCC) announced today that its CEO,
Kipp deVeer, is scheduled to present at the JMP Securities Financial
Services and Real Estate Conference on Tuesday, September 30, 2014 at
8:30 am EDT in New York City.
Inc. (NASDAQ: SPLK), provider of the leading software platform for
real-time Operational Intelligence, today announced that .conf2014: The
Fifth Annual Splunk Worldwide Users’ Conference will feature keynotes by
Godfrey Sullivan, chairman and CEO, Splunk, and Mark Graff, chief
information security officer, NASDAQ.
Insmed Incorporated (Nasdaq:INSM), announces that Company management
will participate in the upcoming Leerink Partners’ Rare Disease
Roundtable taking place October 1, 2014 at Le Parker Meridian Hotel in
New York City.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.